School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Syst Rev. 2020 Apr 8;9(1):75. doi: 10.1186/s13643-020-01343-4.
A new type of coronavirus, novel coronavirus (COVID-19), is causing an increasing number of cases of pneumonia and was declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China, in late December 2019, and traditional Chinese herbal medicine is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of traditional Chinese herbal medicine in COVID-19 pneumonia.
We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang database using keywords related to COVID-19 and traditional Chinese herbal medicine. Reference lists of relevant trials and reviews will be searched. We will manually search gray literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies (XL and DZ), extract data (YL and LG), and evaluate risk of bias (YL and DZ). Data analysis will be conducted using the Review Manager software (version 5.3.5) and R software (version 3.6.1). Statistical heterogeneity will be assessed using a standard chi-square test with a significance level of P < 0.10. Biases associated with study size (e.g., publication bias) will be investigated using funnel plots, Egger's test and Begg's test, and Trim and Fill analysis.
This study will provide a high-quality synthesis of the effects of traditional Chinese herbal medicine for COVID-19. The use of traditional Chinese herbal medicine for treatment or prevention of these novel viral infections affecting the pneumonia will be investigated.
PROSPERO registration number: CRD42020168004.
一种新型冠状病毒，新型冠状病毒（COVID-19），导致越来越多的肺炎病例，并于 2020 年 1 月 30 日被世界卫生组织宣布为国际关注的突发公共卫生事件。该病毒于 2019 年 12 月底首次出现在中国武汉，正在使用中草药进行治疗。本系统评价和荟萃分析将评估中草药治疗 COVID-19 肺炎的研究。
我们将使用与 COVID-19 和中草药相关的关键词，检索电子数据库，包括 PubMed、Embase、Cochrane 中央对照试验注册库（CENTRAL）、中国生物医学文献数据库（CBM）、中国知网（CNKI）、中国科技期刊数据库（VIP）和万方数据库。将检索相关试验和综述的参考文献列表。我们将手动检索灰色文献，如会议记录和学术学位论文，以及试验注册处。两名独立评审员将筛选研究（XL 和 DZ）、提取数据（YL 和 LG）并评估偏倚风险（YL 和 DZ）。数据分析将使用 Review Manager 软件（版本 5.3.5）和 R 软件（版本 3.6.1）进行。使用标准卡方检验（P < 0.10）评估统计学异质性。使用漏斗图、Egger 检验和 Begg 检验以及 Trim 和 Fill 分析评估与研究规模相关的偏倚（例如发表偏倚）。
本研究将提供高质量的中草药治疗 COVID-19 效果的综合评估。将研究用于治疗或预防这些新型病毒性感染引起的肺炎的中草药的使用情况。
PROSPERO 注册号：CRD42020168004。
